Viral Vector and Plasmid DNA Manufacturing Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)

Publication ⇒Nov-23 Delivery Time ⇒ 5-7 Business Days Report Code ⇒PBCHC347-10M-OT

License Type (Price in USD)

Viral Vector and Plasmid DNA Manufacturing Market – Report Overview

Pacific Business Consulting’s “Viral Vector and Plasmid DNA Manufacturing Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of Viral Vector and Plasmid DNA Manufacturing market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.

In 2022, the Viral Vector and Plasmid DNA Manufacturing market exceeded a valuation of over US$ 2.0 Billion, and it is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) exceeding 10.0% from 2023 to 2030. The market is expected to potentially surpass US$ 6.0 Billion by 2030.

The viral vectors and plasmid DNA manufacturing market has presented significant opportunities, particularly in response to the COVID-19 pandemic. Market players have shifted their focus towards the development of viral vectors for the SARS-CoV-2 vaccine. Viral vectors have become crucial tools in the discovery and development of vaccines against SARS-CoV-2, with companies like Johnson & Johnson/Janssen, AstraZeneca/University of Oxford, Gamaleya Research Institute, and CanSino Biologics developing viral vector-based COVID-19 vaccines. The pandemic has accelerated investment in this area due to the quick manufacturability and design capabilities of viral vector-based vaccines using the same building blocks.

Several COVID-19 vaccine candidates in clinical trials utilize viral vector vaccines, and many of them have received or are close to receiving approvals. For example, Johnson & Johnson’s AdVac viral vector technology demonstrated favorable efficacy and safety in its Phase 3 ENSEMBLE clinical trial, leading to the approval of its single-dose COVID-19 vaccine. The Oxford-AstraZeneca COVID-19 vaccine, another viral vector-based vaccine, has also received various approvals and has been mass-produced for global vaccination efforts.

The market for viral vectors and plasmid DNA manufacturing is growing due to the increasing prevalence of target diseases and the efficacy of viral vectors in gene therapy delivery. Continued research in viral vector-based cell and gene therapies, along with financing for gene therapy advancements, contributes to market growth. The rise in gene therapy development and the increasing demand for plasmid DNA, especially for AAV, lentivirus, and other viral vector systems, further drive market expansion.

The growing number of patients opting for gene therapy, coupled with the surge in gene therapy development, has led to increased demand for plasmid DNA. The prevalence of genetic illnesses and infectious diseases worldwide, such as HIV, contributes to the rising demand for viral vectors and plasmid DNA.

Despite the opportunities, challenges such as the risk of insertional mutagenesis and the high cost of gene treatments may impede market expansion. However, technical innovations addressing these constraints in traditional vector production processes present attractive prospects for industry manufacturers.

One of the key drivers for market growth is the advancement in gene therapy, as the development of new gene therapies relies heavily on high-quality viral vectors and plasmid DNA. Ongoing improvements in manufacturing processes have enabled more efficient production of viral vectors and plasmid DNA at larger scales, reducing costs and enhancing overall quality.

Leading players in the Viral Vector and Plasmid DNA Manufacturing segment, including Cobra Biologics, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., and Thermo Fisher Scientific, Virovek Incorporation, BioNTech IMFS GmbH, Audentes Therapeutics, BioMarin Pharmaceutical, RegenxBio, Inc., are expected to play a crucial role in shaping the future landscape of Viral Vector and Plasmid DNA Manufacturing technologies through ongoing innovation.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Viral Vector and Plasmid DNA Manufacturing market. It also delves into the analysis of present and prospective market competition within the global Viral Vector and Plasmid DNA Manufacturing market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

  • Develop your business strategies by gaining insights into the trends that shape and drive the Viral Vector and Plasmid DNA Manufacturing market across the 10MM (Ten Major Markets).
  • Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM Viral Vector and Plasmid DNA Manufacturing market.
  • Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
  • Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.
  1. Executive Summary: Viral Vector and Plasmid DNA Manufacturing
    • Global Market Outlook: Viral Vector and Plasmid DNA Manufacturing
  2. Competitive Intelligence Analysis: Viral Vector and Plasmid DNA Manufacturing
  3. Therapeutic Sector SWOT
  4. Technology Roadmap Analysis: Viral Vector and Plasmid DNA Manufacturing
  5. Market Background
    • Drivers
    • Restraints
    • Opportunity
    • Key Market Trends
    • Key Unmet Needs
  6. Key Marketed Products Profile – Major Approved Products: Viral Vector and Plasmid DNA Manufacturing
    • Product Profile
    • Safety and Efficacy
  7. Regulatory Landscape
  8. Viral Vector and Plasmid DNA Manufacturing: Ten Major Market (10MM) – Market Analysis, By Product
    • Plasmid DNA
    • Viral Vector
    • Non-viral Vector
  9. Viral Vector and Plasmid DNA Manufacturing: Ten Major Market (10MM) – Market Analysis, By Application
    • Gene Therapy
    • Antisense & RNAi Therapy
    • Cell Therapy
    • Other Applications
  10. Viral Vector and Plasmid DNA Manufacturing: Ten Major Market (10MM) – Market Analysis, By End User
    • Pharmaceutical & Biopharmaceutical Companies
    • CROs & CMOs
    • Academic & Research Institutes
  11. Viral Vector and Plasmid DNA Manufacturing: Ten Major Market (10MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. S. Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. K. Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. Germany Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. France Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. Italy Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. Spain Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. Japan Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. China Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. Australia Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. India Viral Vector and Plasmid DNA Manufacturing – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Product
      • By Application
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Product
      • By Application
      • By End User
  1. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

  1. Assumptions and Acronyms Used
  2. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
  3. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, China, Australia, and India
  4. Copyrights and Disclaimer

Customize Reports As Per Your Needs

Don’t see what you’re looking for? Get a report tailored to your specific requirements. Customize your report now!

Have A Question?

We are happy to assist you.

Phone:+919599779105
Email:info@pacificbusinessconsulting.com